European Commission
EU IVDR Implementation Woes Could Severely Limit Cancer Companion Test, Precision Therapy Access
Premium
The EC has stuck with its timeline to implement the new regulations in eight months, raising concerns for cancer patients' ability to receive biomarker testing and treatments.
Investigators are exploring mechanisms to make data available, while acknowledging that scaling up and sustaining the initiative will take place beyond 2022.
European Commission Objects to Illumina Pushing Through Grail Purchase, Mulls Response
European regulators called Illumina's decision to finalize its purchase of Grail "unprecedented" and said they could ultimately impose financial penalties.
At the European Society of Human Genetics meeting, experts discussed how to resolve questions raised by the EU's General Data Protection Regulation around genomic data sharing.
European Commission to Investigate Illumina for Closing Grail Deal
The new investigation will be separate from the ongoing Phase-II investigation into whether the deal violates Europe's merger control regulations.